Clinton Bybee's Net Worth

$3.45 Million

Who is Clinton Bybee?

Clinton Bybee has an estimated net worth of $3.45 Million. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., KYTHERA BIOPHARMACEUTICALS INC, PHASERX, INC., Neumora Therapeutics, Inc., Lyell Immunopharma, Inc., ADESTO TECHNOLOGIES Corp, AGIOS PHARMACEUTICALS INC, NeurogesX Inc, VBI VACCINES INC., Receptos, Inc., Gossamer Bio, Inc., Scholar Rock Holding Corp, Pulmatrix, Inc., Karuna Therapeutics, Inc., bluebird bio, Inc., Denali Therapeutics Inc., FATE THERAPEUTICS INC, Sage Therapeutics, Inc., Vir Biotechnology, Inc., Beam Therapeutics Inc., Metacrine, Inc., Bellerophon Therapeutics, Inc., Unity Biotechnology, Inc., Syros Pharmaceuticals, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., Juno Therapeutics, Inc., Homology Medicines, Inc., Achaogen Inc, Trubion Pharmaceuticals, Inc, CELEBRATE EXPRESS, INC., Boundless Bio, Inc., 908 Devices Inc., Quanterix Corp, Twist Bioscience Corp, XTERA COMMUNICATIONS, INC., ALNYLAM PHARMACEUTICALS INC, IMPINJ INC, XCYTE THERAPIES INC, and ILLUMINA INC.

SEC CIK

Clinton Bybee's CIK is 0001219043

Past Insider Trading and Trends

2019 was Clinton Bybee's most active year for acquiring shares with 6 total transactions. Clinton Bybee's most active month to acquire stocks was the month of May. 2018 was Clinton Bybee's most active year for disposing of shares, totalling 1 transactions. Clinton Bybee's most active month to dispose stocks was the month of May. 2017 saw Clinton Bybee paying a total of $97,720.00 for 6,440 shares, this is the most they've acquired in one year. In 2019 Clinton Bybee cashed out on 4,754 shares for a total of $0.00, their largest year based on trade value.